Frontier IP Alusid raises £1.34 million to scale up manufacturing

Frontier IP chief executive Neil Crabb said: “We’re delighted with the success of the Alusid funding round and the belief shown by investors in the potential of the Company. With consumers increasingly focused on sustainability and the impact of waste on the environment, we are confident that Alusid has a very bright future.”

Frontier IP (LON:FIPP), which specialises in commercialising university intellectual property, today announced that portfolio company, Alusid Limited, has raised £1.34 million through a private funding round to support the design, planning and location of a new factory to transform its production capacity.

The fundraising has been supported by new and existing investors, including Frontier IP. The Group has converted a £348,000 loan into new equity in Alusid.

The fundraising values the Company at £4.86 million, meaning Frontier IP’s 35.6 per cent stake is worth £1.73 million, up from the previous valuation of £700,000 for the 39 per cent held pre-fundraising. The funding round remains open for further investment up to a total of £1.75 million until 31 December 2018.

University of Central Lancashire spin-out Alusid uses a patented process to manufacture sustainable, high-quality building materials by recycling industrial waste ceramics and glass, which would otherwise go to landfill. Products are sold under the brand name SilicaStone.

Currently, the company makes table tops, tiles and other surfaces through a batch process using three kilns at its plant in Preston, Lancashire.

The proceeds of the fundraising will be invested in developing a new factory based on a continuous flow process, where products are fired by being fed onto a conveyer belt system, called a roller hearth tunnel kiln, in a steady stream.

The move follows the successful testing of a pilot production line with world-leading Italian ceramic -equipment company, Sacmi Group, which will also help to design the new factory. The Alusid process means the factory will be much more energy efficient than those used for making conventional tiles.

The plant is expected to start production in 2020. Once it is in operation, Alusid’s capacity will rise from 4,000m2 a year to 30,000m2 a month, based on a single line producing tiles. Currently, it is estimated the cost of building a factory is about £10 million. Options being explored to finance the build include an initial public offering.

Alusid is attracting strong interest, and currently has more than 100 projects in its pipeline. SilicaStone buyers include Amazon, Four Seasons Hotels, Nando’s and Wells Fargo bank, which is using the material in its prestigious new London HQ. The Company won this year’s Jonathan Hindle Prize for outstanding design in 2D materials, awarded by The Furniture Makers’ Company.

The Company is also actively exploring opportunities for international expansion, either through licensing or establishing joint ventures. Initial interest has been expressed by organisations in the United States, China and Portugal.

Allenby Capital Limited acted as broker to Alusid in connection with the funding round.

Alusid co-founder and chief operating officer Dr Alasdair Bremner said: “The building industry is increasingly looking for innovative sustainable products such as SilicaStone. This successful fund-raising will enable Alusid to move to the next stage in development where we can really capitalise on the economies of scale coupled with lower energy and material costs.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Frontier IP Group Plc

    More articles like this

    Frontier IP Group Plc

    Animal Lovers and Zoonotic Diseases: 5 Things to Know

    Zoonotic diseases, or zoonoses, are on the rise. That may first bring to mind exotic diseases like Ebola, but the reality is that many zoonotic infections happen closer to home, often during everyday activities. In 2018,

    Frontier IP Group Plc

    AI-based initiatives catalyzing immunotherapy in 2018

    Artificial intelligence (AI) has been dynamically changing the field of drug discovery in several areas, including immunotherapy, oncotherapy, neurological disease, and many more. Described here is an ensemble of the initiatives in place to advance the field of

    Frontier IP Group Plc

    Frontier IP Group Plc appoint N+1 Singer as sole broker

    Frontier IP Group PLC (LON:FIPP), a specialist in commercialising university intellectual property, today announced the appointment of Nplus1 Singer Advisory LLP as the Group’s sole broker with immediate effect. Allenby Capital Limited remains the Group’s Nominated Adviser.

    Frontier IP Group Plc

    Britain’s university spinout sector is thriving

    They are among Britain’s greatest national treasures and a powerful engine of ideas and innovation for the nation’s booming technology industry. But how good are UK universities at commercialising the research and expertise which springs from

    Frontier IP Group Plc

    Exscientia CEO explains how AI is transforming drug discovery

    In recent decades a strange confluence has formed in the pharmaceutical industry. A range of powerful technologies have brought enormous new capabilities to the sector, productivity has been simultaneously declining. Deloitte’s Centre for Health Solutions estimates that projected returns on investment

    Frontier IP Group Plc

    How technology is revolutionising the healthcare industry

    A technology revolution is transforming the healthcare industry, changing everything from how patients are diagnosed and treated to our battle against some of the world’s most serious diseases. It’s a revolution fuelled by new sources of

    Frontier IP Group Plc

    Artificial Intelligence will Revolutionise Drug Discovery

    New technologies are making their way into the healthcare industry and healthcare providers are already experimenting with advances such as smart pill technology, 3D-printed medication, and mobile apps. But probably the biggest potential lies in artificial intelligence

    Frontier IP Group Plc

    Rallybio forges joint venture with U.K. tech firm

    A Farmington biotech startup formed by a trio of former top Alexion executives said it is working on drug discovery with an artificial intelligence company in the United Kingdom. Rallybio, focused on rare diseases, has not yet publicly

    Frontier IP Group Plc

    What is leptospirosis and how can it harm us and our pets?

    Recently reported cases of the often fatal bacterial infection leptospirosis in dogs in Sydney have raised the issue of animal diseases that also affect humans. This zoonotic disease is spread by rats and other rodents. However, this

    Frontier IP Group Plc

    The Robot Uprising Is Here

    The robot uprising is inevitable. Take the world’s first raspberry-picking robot, an autonomous machine that’s in development by Fieldwork Robotics at the University of Plymouth in the UK. This fruit-picking Terminator, so to speak, was developed for

    Frontier IP Group Plc

    The UK’s 50 Most Disruptive Companies Revealed

    After receiving applications from a wide range of early stage and more established companies from across industries, the initial list was whittled down to 100 by D/SRUPTION. The list was then submitted to an expert judging

    Frontier IP Group Plc

    Artificial intelligence in the world of drug discovery

    Charlotte Walker-Osborn, a Partner and Head of Technology Sector (International) at global law-firm Eversheds Sutherland and a legal expert in technology law, explains some of the challenges and potential future of artificial intelligence (AI) in the

    Frontier IP Group Plc

    11 diseases which can cause infection

    Illnesses that can pass from animals to humans are known as zoonotic. They’re surprisingly common: More than six out of every 10 known infectious diseases in people are actually contracted from animals, according to the CDC.